Liver Disease Treatment in India: Hepatitis B & Cirrhosis Guide for African Patients 2026
Liver Disease Treatment in India: Hepatitis B & Cirrhosis Guide for African Patients 2026
Hepatitis B is silent, common, and dangerous. An estimated 8% of sub-Saharan Africans — roughly 60 million people — carry the hepatitis B virus (HBV). Most are unaware. The virus can quietly damage the liver over years and decades, progressing from inflammation to fibrosis, to cirrhosis, and ultimately to liver failure or hepatocellular carcinoma (liver cancer). It is the leading cause of liver-related death across much of Africa.
The good news is that hepatitis B is now a treatable disease. Modern antiviral drugs can suppress viral replication, halt or reverse fibrosis, and dramatically reduce the risk of cirrhosis and liver cancer. The challenge for many African patients is access — to diagnosis, to specialised hepatology input, and to affordable treatment.
India's hepatology centres are among Asia's finest. The combination of specialist depth, advanced diagnostics (including fibroscan and FibroTest), full therapeutic capability up to and including liver transplantation, and costs that are a fraction of Western equivalents makes India a compelling destination for African patients with chronic liver disease.
Key numbers: Hepatitis B antiviral therapy in India: $20–80/month (tenofovir or entecavir generics). Fibroscan liver stiffness assessment: $50–100. Comprehensive initial hepatology workup: $300–600. Liver transplant if required: from $25,000.
Hepatitis B in Africa: Understanding the Burden
Sub-Saharan Africa has one of the world's highest HBV prevalence rates — the result of perinatal transmission (from mother to child at birth) and horizontal transmission in childhood before immunity develops. Unlike adults who clear HBV infection spontaneously, infants infected perinatally have a 90% risk of developing chronic infection.
Chronic HBV infection follows different natural history phases:
Immune-tolerant phase. High viral load (HBV DNA), normal liver enzymes (ALT), minimal liver damage. Common in young adults with perinatal infection. Treatment is generally not yet indicated but monitoring is essential.
Immune-active phase. Elevated ALT, active liver inflammation, progressive fibrosis. This is when antiviral therapy should begin. Without treatment, patients risk rapid fibrosis progression.
Inactive carrier phase. Low viral load, normal ALT, minimal ongoing damage. Close monitoring continues — reactivation is possible, particularly during immunosuppression.
HBeAg-negative hepatitis. Intermittent flares of viral replication and liver inflammation driven by immune-escape mutants of HBV. Treatment is often required.
Understanding which phase a patient is in requires specialist assessment — not just an HBsAg test, but HBV DNA quantification, HBeAg/anti-HBe, liver function tests, and liver stiffness assessment. India's hepatology centres provide this complete evaluation.
What Hepatitis B Treatment Looks Like in India
Antiviral therapy is the foundation. Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the preferred first-line agents — safe, effective, and taken as a single daily tablet. Entecavir is an equally effective alternative. In India, all three are available as generics at $20–80 per month. Lamivudine, an older agent with resistance concerns, is generally avoided as monotherapy.
Treatment suppresses HBV DNA to undetectable levels in 95%+ of patients, normalises ALT, and — critically — halts fibrosis progression. Early-stage fibrosis often regresses with effective viral suppression over 3–5 years of treatment.
Fibroscan (transient elastography) is the cornerstone of non-invasive fibrosis staging in India. The test takes 10 minutes, requires no anaesthesia, and measures liver stiffness in kilopascals (kPa). Results are immediately available:
- F0–F1 (no/minimal fibrosis): <7.0 kPa
- F2 (significant fibrosis): 7.0–9.5 kPa
- F3 (severe fibrosis): 9.5–12.5 kPa
- F4 (cirrhosis): >12.5 kPa
For African patients arriving with hepatitis B but no prior staging, fibroscan provides an immediate, non-invasive answer to the critical question: how much damage has already occurred?
Liver biopsy remains the gold standard for staging in ambiguous cases but is rarely needed when fibroscan results are clear and concordant with clinical data. India's hepatology centres perform percutaneous liver biopsy when indicated, at costs of $300–600.
Cirrhosis: When Hepatitis B Has Progressed
Cirrhosis develops when fibrosis is so extensive that the liver's architecture is disrupted and normal function is impaired. Compensated cirrhosis (without symptoms of liver failure) can be stable for years if the underlying cause is treated. Decompensated cirrhosis — presenting as jaundice, ascites (fluid in the abdomen), variceal bleeding, or hepatic encephalopathy — is a medical emergency requiring specialist management.
Compensated cirrhosis management in India involves:
- Antiviral therapy to suppress HBV and prevent further damage
- Portal hypertension assessment (gastroscopy to grade oesophageal varices)
- Prophylactic beta-blockers for significant varices
- 6-monthly liver ultrasound and AFP monitoring for hepatocellular carcinoma surveillance
- Fibroscan and clinical monitoring every 6–12 months
Decompensated cirrhosis management is more intensive:
- Management of ascites with diuretics (spironolactone, furosemide) and low-salt diet
- Therapeutic paracentesis for refractory ascites (draining fluid from the abdomen)
- Band ligation of oesophageal varices to prevent bleeding
- Management of spontaneous bacterial peritonitis with antibiotics
- Hepatic encephalopathy treatment with lactulose and rifaximin
- TIPS (transjugular intrahepatic portosystemic shunt) procedure for refractory complications at centres including Medanta, Apollo, and Fortis
Hepatocellular Carcinoma (HCC): Liver Cancer from Hepatitis B
Chronic hepatitis B — even without cirrhosis — carries a significantly elevated risk of hepatocellular carcinoma (HCC). In Africa, HCC is often diagnosed late because surveillance programmes are limited. India's major hepatology centres manage HCC across all stages:
TACE (transarterial chemoembolisation) is the standard treatment for intermediate-stage HCC not amenable to surgery, delivering chemotherapy directly to the tumour via the hepatic artery while blocking its blood supply.
Radiofrequency ablation (RFA) is used for small HCC nodules (below 3cm) as a curative approach with outcomes comparable to surgical resection.
Surgical resection is appropriate for single HCC in a liver with sufficient reserve function — assessed by the Child-Pugh score and MELD score.
Sorafenib and lenvatinib are systemic targeted therapies for advanced HCC. India produces generic sorafenib at dramatically lower cost than branded versions — $200–500/month versus $5,000–8,000/month in the USA.
Liver transplant is the definitive treatment for HCC within Milan criteria (single tumour ≤5cm, or up to 3 tumours none exceeding 3cm) in a cirrhotic liver. India's transplant centres — Medanta, Apollo, Global Hospital — are among Asia's most experienced. See our liver transplant in India guide for detailed information.
Hepatitis C in Africa: A Different Story
While hepatitis B dominates Africa's viral hepatitis burden, hepatitis C (HCV) is also present, particularly in Egypt (highest HCV prevalence globally) and parts of West and East Africa. Modern direct-acting antiviral (DAA) regimens — sofosbuvir/velpatasvir or sofosbuvir/daclatasvir — cure HCV in 95%+ of patients in 12 weeks.
Generic sofosbuvir-based regimens are manufactured in India and cost $100–400 for a 12-week course, compared with $80,000+ for branded Harvoni in the USA. For African patients with HCV who cannot access generic DAAs at home, India represents a uniquely affordable treatment option.
Top Hepatology Centres in India for International Patients
Medanta The Medicity, Gurugram runs one of India's largest liver disease programmes, including liver transplantation (living donor and deceased donor), TACE, TIPS, and all hepatology services. The liver unit is led by internationally trained hepatologists and transplant surgeons.
Institute of Liver and Biliary Sciences (ILBS), Delhi is a government-funded specialist liver hospital — one of the few in Asia dedicated exclusively to liver disease. It is India's reference centre for research in chronic liver disease and has expertise in portal hypertension, advanced cirrhosis, and HCC management.
Apollo Hospitals, Delhi and Chennai offer comprehensive hepatology services with JCI accreditation, dedicated international patient coordination, and liver transplantation programmes.
Global Hospital, Mumbai is renowned for its liver transplant programme under the direction of transplant pioneers who have performed India's highest-volume living donor transplant series.
Fortis Memorial Research Institute has a hepatology and gastroenterology unit with full hepatocellular carcinoma management capability including TACE and RFA.
Starting Your Care Through Arodya
The first step is sending your current reports: HBsAg, HBV DNA, HBeAg, liver function tests, any available fibroscan or ultrasound reports, and a summary of current medications. From these, Arodya's team identifies the appropriate hospital and specialist, provides a cost estimate for the initial workup and management plan, and coordinates the complete visit including visa and travel logistics.
Submit your case through our intake form. There is no cost for the case review or coordination — Arodya is compensated by its hospital partners, not by patients.
Hepatitis B is not a death sentence. It is a treatable disease — if treatment begins in time. India's hepatology centres have the tools, the expertise, and the accessibility to give African patients with liver disease a genuinely strong chance at a healthy future.
